Cost-effectiveness analysis of micafungin versus caspofungin for treatment of systemic Candida infections in the UK

Current Medical Research and Opinion

Volumn 25, Issue 8, 2009, Pages 2049-2059

  Sidhu, M K ^a   Van Engen, A K ^b   Kleintjens, J ^b   Schoeman, O ^b   Palazzo, M ^c  

^a ASTELLAS PHARMA EUROPE LTD   (United Kingdom)

^b IQVIA   (United States)

^c CHARING CROSS HOSPITAL   (United Kingdom)

Author keywords

Candidiasis; Caspofungin; Cost effectiveness; Economic model; Fungemia; Micafungin; Pharmacoeconomics

Indexed keywords

CASPOFUNGIN; FLUCONAZOLE; MICAFUNGIN;

ARTICLE; CANDIDEMIA; CANDIDIASIS; CONFUSION; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG SENSITIVITY; DRUG WITHDRAWAL; FEVER; HEMOLYSIS; HOSPITALIZATION; HUMAN; HYPOKALEMIA; INJECTION SITE REACTION; INVASIVE CANDIDIASIS; KIDNEY FAILURE; LEUKOPENIA; LIVER DISEASE; LIVER TOXICITY; MALAISE; NEPHROTOXICITY; SEIZURE; THROMBOCYTOSIS; TREATMENT OUTCOME; UNITED KINGDOM;

ADOLESCENT; ADULT; ANTIFUNGAL AGENTS; CANDIDIASIS; CLINICAL TRIALS, PHASE III AS TOPIC; COST-BENEFIT ANALYSIS; ECHINOCANDINS; ECONOMICS, PHARMACEUTICAL; GREAT BRITAIN; HEALTH CARE COSTS; HUMANS; LIPOPEPTIDES; MIDDLE AGED; MODELS, ECONOMIC; YOUNG ADULT;

EID: 67651007594     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007990903072565     Document Type: Article

References (19)

1. Ostrosky-Zeichner L, Rex JH, Bennett J, et al. Deeply invasive candidiasis. Infect Dis Clin North Am 2002;16:821-35
2. Playford EG, Sorrell TC. Optimizing therapy for Candida infections. Semin Respir Crit Care Med 2007;28:678-88
3. Cappelletty D, Eiselstein-McKitrick K. The echinocandins. Pharmacotherapy 2007;27:369-88
4. Vehreschild JJ, Cornely OA. Micafungin sodium, the second of the echinocandin class of antifungals: theory and practice. Future Microbiol 2006;1:161-70
5. Pappas PG, Rotstein CM, Betts RF, et al. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin Infect Dis 2007;45:883-93
6. Cornely OA, Sidhu M, Odeyemi I, et al. Economic analysis of micafungin versus liposomal amphotericin b for treatment of candidaemia and invasive candidiasis in Germany. Curr Med Res Opin 2008;24:1743-53
7. Drummond MF, O'Brien B, Stoddard GL, et al. Methods for the Evaluation of Health Care Programmes. Oxford Medical Publications: Oxford University Press, 1999
8. Goeree R, Burke N, O'Reilly D, et al. Transferability of economic evaluations: approaches and factors to consider when using results from one geographic area for another. Curr Med Res Opin 2007;23:671-82
9. British Medical Association. British National Formulary 54: BMJ Publishing Group Ltd and RPS Publishing, September 2007
10. Newcastle Upon Tyne Trust Tariffs: 2006/2007
11. Boland A, Haycox A, Bagust A, et al. A randomised controlled trial to evaluate the clinical and cost-effectiveness of Hickman line insertions in adult cancer patients by nurses. Health Technology Assessment 2003;7(36):47
12. Schwengel DA, McGready J, Berenholtz SM, et al. Peripherally inserted central catheters: a randomized, controlled, prospective trial in pediatric surgical patients. Anesth Analg 2004;99:1038-43
13. Iselin L, Naef M, Wagner HE, et al. Peripheral access for implantable venous access device. EJVES 2005;Extra 10:54-6
14. OANDA.com, the currency site, 2007. Available at: http://www.oanda.com/ convert/fxhistory
15. Curtis L, Netten A. Unit Costs of Health and Social Care 2005. Personal Social Services Research Unit: The University of Kent, 2005
16. Prentice HG, Hann IM, Herbrecht R, et al. A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients. Br J Haematol 1997;98:711-18
17. Eiland EH, Hassoun A, English T. Points of concern to the micafungin versus caspofungin trial. Clin Infect Dis 2008;46:640-1; author reply 641
18. Bruynesteyn K, Gant V, McKenzie C, et al. A cost-effectiveness analysis of caspofungin vs. liposomal amphotericin B for treatment of suspected fungal infections in the UK. Eur J Haematol 2007;78:532-9
19. Walsh TJ, Teppler H, Donowitz GR, et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 2004;351:1391-402